Varian ProBeam Proton Therapy System Receives Shonin Approval

Font : A-A+

Advanced proton therapy systems from Varian now available to cancer centers in Japan

PALO ALTO, Calif., May 10, 2017 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has received Shonin

approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam^® system for proton therapy in Japan. This approval is the latest example of the growing worldwide interest in proton therapy as an advanced treatment option for cancer patients. Varian will be showcasing the ProBeam system at the Particle Therapy Co-Operative Group (PTCOG), May 11-13, 2017 in Yokohama, Japan.

Varian's ProBeam system is the first to offer fully-integrated intensity modulated proton therapy (IMPT) to enable more efficient adaptive proton therapy. Varian's pencil beam scanning technology gives clinicians the ability to deliver the dose precisely in the tumor to minimize dose to healthy tissue. When combined with cone beam computed tomography (CBCT), the ProBeam system enables advanced image-guided adaptive therapy during the course of treatment helping to make it the most precise form of proton therapy available.

With proton therapy, the risk of damage to healthy tissues and potential side effects are reduced because proton beams can be controlled so that they deposit their energy within the tumor site rather than passing all the way through the patient. The treatment is particularly suitable for pediatric cancer cases as well as for adults.

"We are very pleased that the ProBeam system has now received Shonin approval," said Moataz Karmalawy, general manager of Varian's Particle Therapy division. "This approval is an important step in the growing availability of proton therapy in Japan and around the world."

For more information on ProBeam, visit www.varian.com/proton

About Varian Medical SystemsVarian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact

Mark PlungyVarian Medical Systems+1 (650) 424-5630 mark.plungy@varian.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/varian-probeam-proton-therapy-system-receives-shonin-approval-300455076.html

SOURCE Varian Medical Systems

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.